Akebia Therapeutics, Inc.
AKBA
$2.06
$0.168.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.67% | 21.53% | 58.82% | 26.66% | 44.89% |
| Total Depreciation and Amortization | -0.34% | 11.00% | 11.04% | 10.97% | 11.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 260.08% | 140.92% | 133.54% | 138.96% | 148.89% |
| Change in Net Operating Assets | -91.42% | -430.86% | -194.30% | -26.30% | -1,336.38% |
| Cash from Operations | -73.88% | 49.18% | -12.05% | 63.40% | 68.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -15.93% | -87.92% | 20.88% | -7.60% | 3.03% |
| Issuance of Common Stock | 533.41% | 32,542.86% | 26,420.62% | 26,406.19% | -10.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 297.03% | 208.91% | 143.71% | 118.88% | -272.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.46% | 87.47% | 84.59% | 86.40% | 17.18% |